By Fineline Cube 
China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and TransReco (Wenzhou) Biotechnology Co., Ltd. announced a strategic partnership late last month. The collaboration focuses on addressing significant unmet clinical needs in ophthalmology, autoimmune diseases, metabolic disorders, anti-aging, and infectious diseases. The partnership aims to integrate Sanyou Bio’s expertise in antibody drug discovery and TransReco Bio’s innovative formulation manufacturing capabilities.
Collaboration Focus
The collaboration will concentrate on advancing the development of cutting-edge drug formulations, including eye drops, topical gels, and inhalation agents. The goal is to create an end-to-end solution that encompasses research and development, manufacturing, and commercialization, thereby accelerating the development of novel drug formulations.
Strategic Partnership Model
This partnership establishes a new collaborative model termed “Biotech + CDMO + National-Level Platforms.” Sanyou Bio will utilize its globally leading AI-STAL platform, a trillion-scale intelligent molecular library, to enhance drug discovery efforts. TransReco Bio brings to the table its advanced capabilities in microbial and eukaryotic protein production, BFS ophthalmic formulations, and lyophilized and injectable formulations. TransRecoBio is supported by two national-level platforms: the National Key Laboratory for Large Molecule Drug Manufacturing and the National Engineering Research Center for Growth Factor Drugs and Protein Formulations.-Fineline Info & Tech